Page last updated: 2024-08-25

rosiglitazone and Infant, Newborn, Diseases

rosiglitazone has been researched along with Infant, Newborn, Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Armstrong, M; de Langhe, S; Dill, E; Gelfand, EW; Irwin, D; Klemm, D; Koster, M; Majka, SM; Nozik-Grayck, E; Okamoto, M; Reisdorf, N; Stenmark, KR; Takeda, K; West, J; Wilder, J	1

Other Studies

1 other study(ies) available for rosiglitazone and Infant, Newborn, Diseases

Article	Year
Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease. Anatomical record (Hoboken, N.J. : 2007), 2009, Volume: 292, Issue:7 Topics: Animals; Animals, Newborn; Bronchoconstriction; Cell Differentiation; Disease Models, Animal; Fibroblasts; Humans; Hyperoxia; Infant, Newborn; Infant, Newborn, Diseases; Lung; Lung Diseases; Mice; Mice, Inbred C57BL; Muscle, Smooth; Neovascularization, Physiologic; PPAR gamma; Respiratory System; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents	2009

Article

Year

Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease.

Anatomical record (Hoboken, N.J. : 2007), 2009, Volume: 292, Issue:7

Topics: Animals; Animals, Newborn; Bronchoconstriction; Cell Differentiation; Disease Models, Animal; Fibroblasts; Humans; Hyperoxia; Infant, Newborn; Infant, Newborn, Diseases; Lung; Lung Diseases; Mice; Mice, Inbred C57BL; Muscle, Smooth; Neovascularization, Physiologic; PPAR gamma; Respiratory System; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents

2009